The DIRECTOR slides
are faster, more precise and accurate than any other microdissection
technology. They dramatically simplify
collection of tissue features from all kinds of tissue, and
are well suited for both genomic and proteomic applications.
The DIRECTOR slides are fully compatible with the three
leading laser microdissection platforms on the market; the Leica
LMD6000,
the P.A.L.M.
Microbeam from Zeiss, and the new generation mmi
CellCut Plus from Molecular Machines & Industries.
Principles of Fast Forward Microdissection
The tissue is mounted on top of a thin energy transfer
coating. When the laser is pulsed, the energy coating is
vaporized and the tissue is instantly propelled into the
cap. Download 3Mb .wmv file of the streaming video below.
Actual microdissection of a prostate cancer section from a DIRECTOR
slide (20X magnification) on a Leica LMD6000 system. Regions
are marked and collected using the scanning/raster function
of the most
recent LMD6000
software.
The
different colors are collected in different caps. Regions can
be marked up all over the slide, also outside of the immediate
field of vision. The videos
were recorded in our laboratories using a Leica LMD6000 laser
microdissector,
and SnagIt.
Clip 1. Download a 14 mb .wmv file of the video above here: Draw
and Scan Mode
-
Clip 2. Download a 6 Mb .wmv file here: Move
and Cut Mode - Tissue is cut continuously as the cursor
is moved. Excellent for collecting e.g. cancerous epithelium.
Clip 3. Download a 3 Mb file here: Draw
then cut - For when multiple thin regions
need to be marked up and collected.
These video files are downsampled from the original high-resolution
files.
The software
tracks
the total area
collected.
This makes it easy
to estimate how much tissue has been collected.
For more information regarding the Leica LMD6000
microdissector, please
contact your
local Leica
Microsystems representative.
Liquid Tissue technology is protected by U.S. Patent 7,473,532
and patents pending and foreign equivalents thereof.
DIRECTOR technology is protected by U.S. Patents 7,294,367 and
7,381,440 and foreign equivalents thereof.
Expression
Pathology Inc. is a leader in tissue proteomics.
Using our tissue analysis
platform we are developing targeted tissue proteomic assays for oncology. The tests will provide information to guide treatment decisions – the
presence of protein drug targets, or which biological pathways
are activated in tumors to aid prognosis and drug selection.
Our scientists have extensive experience in pathology,
proteomics and tissue analysis. Call us to discuss your project.
We can help you design your experiment, and we can also help you
with grant writing.
The Liquid Tissue® MS protocol prepares FFPE samples
for mass spec analysis. Complete solubilization captures the entire
protein content. Mass spec friendly. Requires only 30,000 cells for
multiple mass spectrometry analyses.
The Director® Laser Microdissection
Slides provide the fastest, easiest and
most accurate way to collect specific cellular
features from tissue sections. The DIRECTOR
slides are fully compatible with the three
leading laser microdissection platforms
on the market; the Leica
LMD6000, the P.A.L.M.
Microbeam from Zeiss, and the new generation mmi
CellCut Plus from Molecular Machines & Industries.
news sidebar
News & Events
Expression Pathology Collaborates with Toronto’s Sick Kids Hospital and University Health Network on New Mass Spec EGFR Test, May 4, 2010, (press release)
Thermo
Fisher announced a collaboration with Expression Pathology to develop
Liquid Tissue MRM Assays of Cancer Proteins In Microdissected FFPE Tissue,
December 16, 2009 (press
release)
The Mayo
Clinic has licensed non-exclusive rights to the Liquid Tissue(R) patent
for use in diagnosis of systemic amyloidosis in FFPE tissue, November 17, 2009 (press
release)
Expression
Pathology raises $6.5 Million
to develop personalized medicine assays for protein biomarkers in FFPE
Tissue. April 20, 2009 (press
release)
